Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shinsuke Iida

Showing results (181-190 of 290) with videos related to

Pageof 29
Sort By:
Cancer Research|October 2, 2014
Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myelomaYoshiaki Chinen, Junya Kuroda, Yuji Shimura, et al.
International Journal of Hematology|July 29, 2023
A retrospective analysis of clinical features and treatment outcome in 21 patients with immunoglobulin M-related light-chain amyloidosis in Japan: a study from the Amyloidosis Research CommitteeShin-Ichi Fuchida, Mizuki Ogura, Tadao Ishida, et al.
Hematological Oncology|November 25, 2022
Aberrant tryptophan metabolism leads to unfavorable outcomes in lenalidomide-treated myeloma patientsArisa Asano, Masaki Ri, Ayako Masaki, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 18, 2011
ABO genotype and the risk of gastric cancer, atrophic gastritis, and Helicobacter pylori infectionMakoto Nakao, Keitaro Matsuo, Hidemi Ito, et al.
Cancer Science|February 16, 2020
Expression, mutation, and methylation of cereblon-pathway genes at pre- and post-lenalidomide treatment in multiple myelomaTakuto Tachita, Shiori Kinoshita, Masaki Ri, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 23, 2024
Clinical Significance of Cytomegalovirus Reactivation in Patients With Plasma Cell Dyscrasia Who Were Treated With Anti-CD38 Monoclonal Antibody: A Retrospective Analysis in a Single InstitutionNaohiro Matsunaga, Tomotaka Suzuki, Nozomi Nishitarumizu, et al.
International Journal of Hematology|November 28, 2024
A Phase 1/2 study of teclistamab, a humanized BCMA × CD3 bispecific Ab in Japanese patients with relapsed/refractory MMTadao Ishida, Yoshiaki Kuroda, Kosei Matsue, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 24, 2013
HTLV-1 bZIP factor-specific CD4 T cell responses in adult T cell leukemia/lymphoma patients after allogeneic hematopoietic stem cell transplantationTomoko Narita, Takashi Ishida, Ayako Masaki, et al.
International Journal of Hematology|May 24, 2019
Impact of chromosomal abnormalities on the efficacy of lenalidomide plus dexamethasone treatment in patients with relapsed/refractory multiple myelomaTakashi Yoshida, Masaki Ri, Haruna Fujinami, et al.
International Journal of Hematology|May 20, 2011
Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysisYukio Kobayashi, Hisashi Sakamaki, Shin Fujisawa, et al.
Pageof 29

Showing results (181-190 of 290) with videos related to

Sort By:
Pageof 29
Cancer Research|October 2, 2014
Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myelomaYoshiaki Chinen, Junya Kuroda, Yuji Shimura, et al.
International Journal of Hematology|July 29, 2023
A retrospective analysis of clinical features and treatment outcome in 21 patients with immunoglobulin M-related light-chain amyloidosis in Japan: a study from the Amyloidosis Research CommitteeShin-Ichi Fuchida, Mizuki Ogura, Tadao Ishida, et al.
Hematological Oncology|November 25, 2022
Aberrant tryptophan metabolism leads to unfavorable outcomes in lenalidomide-treated myeloma patientsArisa Asano, Masaki Ri, Ayako Masaki, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 18, 2011
ABO genotype and the risk of gastric cancer, atrophic gastritis, and Helicobacter pylori infectionMakoto Nakao, Keitaro Matsuo, Hidemi Ito, et al.
Cancer Science|February 16, 2020
Expression, mutation, and methylation of cereblon-pathway genes at pre- and post-lenalidomide treatment in multiple myelomaTakuto Tachita, Shiori Kinoshita, Masaki Ri, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 23, 2024
Clinical Significance of Cytomegalovirus Reactivation in Patients With Plasma Cell Dyscrasia Who Were Treated With Anti-CD38 Monoclonal Antibody: A Retrospective Analysis in a Single InstitutionNaohiro Matsunaga, Tomotaka Suzuki, Nozomi Nishitarumizu, et al.
International Journal of Hematology|November 28, 2024
A Phase 1/2 study of teclistamab, a humanized BCMA × CD3 bispecific Ab in Japanese patients with relapsed/refractory MMTadao Ishida, Yoshiaki Kuroda, Kosei Matsue, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 24, 2013
HTLV-1 bZIP factor-specific CD4 T cell responses in adult T cell leukemia/lymphoma patients after allogeneic hematopoietic stem cell transplantationTomoko Narita, Takashi Ishida, Ayako Masaki, et al.
International Journal of Hematology|May 24, 2019
Impact of chromosomal abnormalities on the efficacy of lenalidomide plus dexamethasone treatment in patients with relapsed/refractory multiple myelomaTakashi Yoshida, Masaki Ri, Haruna Fujinami, et al.
International Journal of Hematology|May 20, 2011
Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysisYukio Kobayashi, Hisashi Sakamaki, Shin Fujisawa, et al.
Pageof 29